Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2021

08.04.2021 | original report

Update ESMO: gastric and esophageal cancer

verfasst von: MD Ulrich Popper, MD Holger Rumpold

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

During this year’s virtual congress of the European Society of Oncology (ESMO) some practice-changing abstracts were presented. Especially immunotherapy (IO) has found its way into the treatment of esophageal (EC) and gastric cancer (GC) in both the adjuvant and palliative setting. The CheckMate 577 trial, which was presented in EMSO Presidential Symposium III, showed a doubling in disease-free survival (DFS) for patients with resected esophageal (EC) or esophagogastric junction cancer (EGJC) following neoadjuvant chemoradiation therapy (CRT), who had not achieved a pathological complete response, treated with nivolumab versus placebo. For advanced disease, the KEYNOTE-590 trial revealed a benefit of adding pembrolizumab to chemotherapy for patients with locally advanced or metastatic adenocarcinoma (EAC) or squamous cell carcinoma of the esophagus (ESCC) or EGJC Siewert type 1. In the CheckMate 649 study, patients (predominantly Caucasians) with advanced gastric, EGJC or EAC benefitted from the addition of nivolumab to chemotherapy in terms of overall survival (OS) and progression-free survival (PFS). In contrast, in the ATTRACTION‑4 trial, the Asian population gained a prolongation of PFS but not of OS by adding IO to chemotherapy.
Literatur
1.
Zurück zum Zitat Shah MA, Kennedy EB, Catenacci DV, Dana C, et al. Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. J Clin Oncol. 2020;38:23:2677–94. CrossRef Shah MA, Kennedy EB, Catenacci DV, Dana C, et al. Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. J Clin Oncol. 2020;38:23:2677–94. CrossRef
2.
Zurück zum Zitat Shapiro J, van Lanschot JJB, Hulshof MCCM. van Hagen et al. CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8. CrossRef Shapiro J, van Lanschot JJB, Hulshof MCCM. van Hagen et al. CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8. CrossRef
3.
Zurück zum Zitat Kato K, Cho BCC, Takahashi M, Okada M, et al. Nivoluma versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refratory to prevoius chemotheraoy (Attraction-3). Lancet Oncol. 2019;20(11):1506–17. CrossRef Kato K, Cho BCC, Takahashi M, Okada M, et al. Nivoluma versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refratory to prevoius chemotheraoy (Attraction-3). Lancet Oncol. 2019;20(11):1506–17. CrossRef
4.
Zurück zum Zitat Kang YK, Boku N, Satoh T, Ryu MH, et al. Nivoluma in patients with advanced gastric or gastro-osophageal junction cancer refractory to, or intolerant of, at least two previous chemotheraoy regimes (Attraction-2). Lancet. 2017;390(10111):2461–71. CrossRef Kang YK, Boku N, Satoh T, Ryu MH, et al. Nivoluma in patients with advanced gastric or gastro-osophageal junction cancer refractory to, or intolerant of, at least two previous chemotheraoy regimes (Attraction-2). Lancet. 2017;390(10111):2461–71. CrossRef
5.
Zurück zum Zitat Murphy MB, Xiao L, Patel VR, Maru DM, et al. Pathological complete response in patient with esophageal cancer after the trimodality approach: The associaton with baseline variables and survival. Cancer. 2017;123(21):4106–13. CrossRef Murphy MB, Xiao L, Patel VR, Maru DM, et al. Pathological complete response in patient with esophageal cancer after the trimodality approach: The associaton with baseline variables and survival. Cancer. 2017;123(21):4106–13. CrossRef
6.
Zurück zum Zitat Njei B, McCarty TR, Birk JW. Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis. J Gastroenterol Hepatol. 2016;31(6):1141–6. CrossRef Njei B, McCarty TR, Birk JW. Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis. J Gastroenterol Hepatol. 2016;31(6):1141–6. CrossRef
7.
Zurück zum Zitat Kies MS, Rosen ST, Tsang TK, Shetty R, et al. Cisplatin and 5‑fluorouracil in the primary management of squamous esophageal cancer. Cancer. 1987;60(9):2156–60. CrossRef Kies MS, Rosen ST, Tsang TK, Shetty R, et al. Cisplatin and 5‑fluorouracil in the primary management of squamous esophageal cancer. Cancer. 1987;60(9):2156–60. CrossRef
8.
Zurück zum Zitat Shah MA, Adenis A, Enzinger PC. Kojima T et al Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study. J Clin Oncol. 2019;37(no.15_suppl):4010–4010. CrossRef Shah MA, Adenis A, Enzinger PC. Kojima T et al Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study. J Clin Oncol. 2019;37(no.15_suppl):4010–4010. CrossRef
9.
Zurück zum Zitat Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635–48. CrossRef Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635–48. CrossRef
10.
Zurück zum Zitat Fuch CS, Shitara K, Di Bartolomeo M, et al. Ramucirumab with cisplatin and flouropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL). Lancet Oncol. 2019;20(3):420–35. CrossRef Fuch CS, Shitara K, Di Bartolomeo M, et al. Ramucirumab with cisplatin and flouropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL). Lancet Oncol. 2019;20(3):420–35. CrossRef
11.
Zurück zum Zitat Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–75. CrossRef Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–75. CrossRef
12.
Zurück zum Zitat Al-Batran SE, Homann N, Schmalenberg H, Kopp HG, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO). J Clin Oncol. 2017;35(no15_suppl):4004–4004. CrossRef Al-Batran SE, Homann N, Schmalenberg H, Kopp HG, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO). J Clin Oncol. 2017;35(no15_suppl):4004–4004. CrossRef
13.
Zurück zum Zitat Weber J, Mandela M, Del Vecchio HJ, Gogas HJ, et al. Adjuvant Nivolumab verus Ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35. CrossRef Weber J, Mandela M, Del Vecchio HJ, Gogas HJ, et al. Adjuvant Nivolumab verus Ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35. CrossRef
Metadaten
Titel
Update ESMO: gastric and esophageal cancer
verfasst von
MD Ulrich Popper
MD Holger Rumpold
Publikationsdatum
08.04.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00694-5